Global Alport Syndrome Market, By Genetic Type (X-linked Alport Syndrome, Autosomal Recessive Alport Syndrome, Autosomal Dominant Alport Syndrome, Others), Diagnosis (Kidney Biopsy, Genetic Testing, Ophthalmic Testing, Others), Route of Administration (Oral, Parenteral, Others), Treatment (Medication, Surgery and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Alport Syndrome Market Analysis and Size
The global alport syndrome market is expected to observe significant growth during the forecast period. People suffering from Alport syndrome suffer from inner ear abnormalities such as sensorineural hearing loss and vision loss. The key molecule types in the Alport syndrome pipeline drugs are small molecule, oligonucleotide, and biologic. Small molecule has the highest share in the Alport syndrome market. As the condition progresses, the kidney function worsens leading to end-stage renal disease (ESRD).
Data Bridge Market Research analyses a growth rate in the global alport syndrome market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Alport Syndrome Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Genetic Type (X-linked Alport Syndrome, Autosomal Recessive Alport Syndrome, Autosomal Dominant Alport Syndrome, Others), Diagnosis (Kidney Biopsy, Genetic Testing, Ophthalmic Testing, Others), Syndrome (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), Treatment (Medication, Surgery and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Centogene N.V. (Germany), Eurofins Discovery (Luxembourg), Hoffmann-La Roche Ltd. (Switzerland), Invitae Corporation (U.S.), Illumina Inc (U.S.), Natera Inc (U.S.), PerkinElmer Inc (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins LifeCodexx GmbH (Germany), Ravgen (U.S.) , AstraZeneca (U.K.), Lilly (U.S.), Mylan N.V. (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel)
|
|
Market Opportunities
|
|
Market Definition
Alport syndrome is the rare, genetic, inherited X-linked disorder caused by the gene mutation of COL4A3, COL4A4, or COL4A5. It is a condition that damages the tiny blood vessels of the kidney, that leads to kidney damage & failure. It also causes hearing loss and eye abnormalities. Patients suffering from this syndrome suffer from progressive loss of kidney function. Presence of blood in urine specifies the abnormal functioning of the kidneys. A number of patients suffering from this syndrome develop increased levels of proteins in the urine.
Global Alport Syndrome Market Dynamics
Drivers
- Increase Prevalence of Alport Syndrome
The rising incidence of Alport syndrome is quite rare and generally occurs in 1 in 50,000 newborns. Approximately 80% of Alport syndrome cases are caused by mutations in the COL4A5 gene that are located in the X chromosome. Thus, this factor boost the market growth.
- Increase in Diagnostic Tests
Different diagnostic tests used for treating global alport syndrome market are boosting the market growth. Demand for genetic testing as an effective diagnostic procedure for alport syndrome is projected to drive the global Alport syndrome market. Furthermore, skin biopsy and kidney biopsy are used to diagnose the early symptoms of alport syndrome and faster adoption of these diagnostic techniques is a major factor boosting the global market.
Opportunities
- Increase in the number of research and development activities
The market growth is fueled by an increase in the number of R&D activities. This will provide beneficial opportunities for the alport syndrome market growth. To encourage researchers and pharmaceutical companies to develop advanced medicines, the government is funding R&D initiatives. Development of different bilateral and unilateral cochlear implants are creating much opportunities in the future for the market growth.
- Emergence of New Varied Treatments
The new evolving research organizations in the market are equipped with and utilize the knowledge of professionals in numerous clinical disciplines, leading to important advances in understanding alport disorders and treatment. Establishing a simple scoring system to select individuals for alport syndrome testing is likely boosting the global market. Currently PCR tests are applied for the detection of these diseases with genetic instability that helps in the detection of the disease and diagnosis for the same.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel unable to perform these treatments could curb the growth of the global alport syndrome market over a forecast period.
- High Cost
The huge expenditure required for the surgeries and treatment processes hamper the market growth. Numerous market players make huge investment in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This global alport syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global alport syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Alport Syndrome Market Scope
The global alport syndrome market is segmented on the basis of genetic type, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Genetic Type
- X-linked Alport Syndrome
- Autosomal Recessive Alport Syndrome
- Autosomal Dominant Alport Syndrome
- Others
Diagnosis
- Kidney Biopsy
- Genetic Testing
- Ophthalmic Testing
- Others
Treatment
- Medication
- Surgery
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Alport Syndrome Market Regional Analysis/Insights
The global alport syndrome market is analyzed and market size insights and trends are provided by genetic type, diagnosis, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global alport syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period due to the increased prevalence of kidney diseases and the presence of key manufacturers of the product.
Asia-Pacific is considered to grow over the coming years due to the increased prevalence of kidney failure and related disorders and the number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Alport Syndrome Market Share Analysis
The global alport syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global alport syndrome market
Key players operating in the global alport syndrome market include:
- Centogene N.V. (Germany)
- Eurofins Discovery (Luxembourg)
- Hoffmann-La Roche Ltd. (Switzerland)
- Invitae Corporation (U.S.)
- Illumina Inc (U.S.)
- Natera Inc (U.S.)
- PerkinElmer Inc (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Eurofins LifeCodexx GmbH (Germany)
- Ravgen (U.S.)
- AstraZeneca (U.K.)
- Lilly (U.S.)
- Mylan N.V. (U.S.)
- Sanofi (France)
- Teva Pharmaceutical Industries Ltd. (Israel)
SKU-